Galena Biopharma, Inc. (NASDAQ:GALE)

CAPS Rating: 1 out of 5

Results 1 - 9 of 9

Recs

1
Member Avatar blackswanexposur (30.12) Submitted: 6/17/2015 4:43:10 PM : Outperform Start Price: $1.85 GALE Score: -7.54

Risky biotech pharma play. Well documented risks include 1) pending shareholder class-action lawsuit, and 2) diminishing cash reserves available to fund approximately one year of operations. Motion to dismiss class-action suit is currently under review by a judge in Oregon, though timeline of ruling is unknown.

Current medications on the market have struggled to gain market share and have not provided anticipated revenue to help fund operations. The real value in this stock, however, is the developing pipeline of cancer immunotherapies led by NeuVax, which is in Phase III trials. NeuVax is being developed to prevent recurrence of specific types of breast cancer. Additional drugs are in Phase II trials.

GALE will likely need a partnership or sell additional shares in the next year to fund ongoing trials, though the current share price does represent a distressed valuation. Potential collaborations, positive interim data for NeuVax, or ultimately FDA approval of NeuVax should result in significant movement of share price. High risk-high reward.

Recs

1
Member Avatar zzlangerhans (99.83) Submitted: 3/26/2015 12:01:07 AM : Outperform Start Price: $1.47 GALE Score: +15.87

There's something about cult stocks that have fallen out of favor that I find strangely attractive. I see them as dormant time bombs, awaiting some undefinable catalyst that will launch the cult back into active status. Of course, more often than not the crippled stock continues to sink as the market continues to ignore it. In the case of Galena, I'm hoping to see some life ooze back into the stock if the PRESENT phase III trial of NeuVax for low/intermediate HER2+ node positive breast cancer passes an interim analysis in early 2016. That's admittedly a long time to wait and biopharma is almost certainly due for rough seas at some point this year, so it's probably not a good time to put real money in Galena. Data from a phase IIb trial of NeuVax with Herceptin in node positive triple negative HER2 IHC 1+/2+ breast cancer is also expected in 2016. Galena is keeping the lights on with a 50M ATM with vulture financier Lincoln Park, which is another ongoing negative for current shareholders. The most positive thing about Galena is the possibility that the company has taken maximal damage from the pay for promotion scandal of 2014.

Recs

0
Member Avatar drugtrader (91.49) Submitted: 3/25/2015 12:31:39 AM : Outperform Start Price: $1.49 GALE Score: +13.59

2 thumbs up from zzporte! I wasn't sure which way to go thanks.

Recs

1
Member Avatar ruinas (53.46) Submitted: 12/27/2014 3:50:21 PM : Underperform Start Price: $1.53 GALE Score: -10.24

Markets overbought - correction due

Recs

0
Member Avatar bargain123 (28.37) Submitted: 12/26/2014 5:46:04 PM : Outperform Start Price: $1.53 GALE Score: +10.24

Technicals look good, product matured, this company will either make money on its own or been bought by Big Guy in this space

Recs

0
Member Avatar DougD720 (< 20) Submitted: 7/17/2014 11:05:35 AM : Outperform Start Price: $2.65 GALE Score: -41.60

Neuvax, highly undervalued due to scandal, still solid company with an excellent pipeline.

Recs

0
Member Avatar herbertslojewski (64.80) Submitted: 7/7/2014 3:56:58 PM : Outperform Start Price: $2.94 GALE Score: -48.24

Great new anti-cancer developments.

Recs

0
Member Avatar manirg (97.98) Submitted: 3/11/2014 9:48:12 AM : Outperform Start Price: $3.37 GALE Score: -60.55

highly undervalued, huge potential, has 2 drugs approved

Recs

0
Member Avatar jgvega (< 20) Submitted: 2/23/2014 3:58:40 PM : Outperform Start Price: $3.92 GALE Score: -69.64

Great chances of being revenue positive towards the end of the year thanks to drug Abstral. Huge market potential for breast cancer drug NueVax (if passed by FDA. it has great chances). Positive ratings from many analysts. Oh, and it’s undervalued due to recently ended bear raid. All and all, great stock and price with multi bagger potential for 2014. check it out.

Results 1 - 9 of 9

Featured Broker Partners


Advertisement